Roles of guanylyl cyclase-A signaling in the cardiovascular system

Canadian Journal of Physiology and Pharmacology

Volumn 89, Issue 8, 2011, Pages 551-556

  Saito, Yoshihiko ^a   Kishimoto, Ichiro ^b   Nakao, Kazuwa ^c  

^a NARA MEDICAL UNIVERSITY   (Japan)

^b NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER   (Japan)

^c KYOTO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; ATRIAL NATRIURETIC FACTOR; BRAIN NATRIURETIC PEPTIDE; EPLERENONE; HYDRALAZINE; MINERALOCORTICOID RECEPTOR; NATRIURETIC PEPTIDE RECEPTOR A; OLMESARTAN;

ACUTE HEART INFARCTION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR SYSTEM; GENETIC CODE; HEART FAILURE; HEART HYPERTROPHY; HEART MUSCLE FIBROSIS; HEART VENTRICLE HYPERTROPHY; HYPERTENSION; NONHUMAN; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; ATRIAL NATRIURETIC FACTOR; CARDIOVASCULAR SYSTEM; HUMANS; NATRIURETIC PEPTIDE, BRAIN; RECEPTORS, ATRIAL NATRIURETIC FACTOR;

EID: 79961178352     PISSN: 00084212     EISSN: 12057541     Source Type: Journal    
DOI: 10.1139/y11-022     Document Type: Review

References (22)

1. Chen, H.H., Martin, F.L., Gibbons, R.J., Schirger, J.A., Wright, R.S., Schears, R.M., et al. 2009. Low-dose nesirtide in human anterior myocardial infarction suppresses aldosterone and preserves ventricular function and structure: a proof of concept study. Heart, 95(16): 1315-1319. doi:10.1136/hrt.2008.153916. PMID: 19447837.
2. Funder, J.W. 2010. Aldosterone and mineralocorticoid receptors in the cardiovascular system. Prog. Cardiovasc. Dis. 52(5): 393-400. doi:10.1016/j.pcad.2009.12.003. PMID:20226957.
3. Holtwick, R., Gotthardt, M., Skryabin, B., Steinmetz, M., Potthast, R., Zetsche, B., et al. 2002. Smooth muscle-selective deletion of guanylyl cyclase-A prevents the acute but not chronic effects of ANP on blood pressure. Proc. Natl. Acad. Sci. U.S.A. 99(10): 7142-7147. doi:10.1073/pnas.102650499. PMID:11997476.
4. Holtwick, R., van Eickels, M., Skryabin, B.V., Baba, H.A., Bubikat, A., Begrow, F., et al. 2003. Pressure-independent cardiac hypertrophy in mice with cardiomyocyte-restricted inactivation of the atrial natriuretic peptide receptor guanylyl cyclase-A. J. Clin. Invest. 111(9): 1399-1407. PMID:12727932.
5. Izumi, T., Saito, Y., Kishimoto, I., Harada, M., Kuwahara, K., Hamanaka, I., et al. 2001. Blockade of the natriuretic peptide receptor guanylyl cyclase-A inhibits NF-kB activation and alleviates myocardial ischemia/reperfusion injury. J. Clin. Invest. 108(2): 203-213. PMID:11457873.
6. John, S.W., Krege, J.H., Oliver, P.M., Hagaman, J.R., Hodgin, J.B., Pang, S.C., et al. 1995. Genetic decreases in atrial natriuretic peptide and salt-sensitive hypertension. Science (Washington, D. C.), 267(5198): 679-681. doi:10.1126/science.7839143. PMID: 7839143.
7. Kawakami, R., Saito, Y., Kishimoto, I., Harada, M., Kuwahara, K., Takahashi, N., et al. 2004. Overexpression of brain natriuretic peptide facilitates neutrophil infiltration and cardiac matrix metalloproteinase-9 expression after acute myocardial infarction. Circulation, 110(21): 3306-3312. doi:10.1161/01.CIR. 0000147829.78357.C5. PMID:15545516.
8. Kitakaze, M., Asakura, M., Kim, J., Shintani, Y., Asanuma, H., Hamasaki, T., et al. 2007. Human atrial natriuretic peptide and nicorandil as adjuncts to reperfusion treatment for acute myocardial infarction (J-WIND): two randomised trials. Lancet, 370(9597): 1483-1493. doi:10.1016/S0140-6736(07)61634-1. PMID:17964349.
9. Li, Y., Kishimoto, I., Saito, Y., Harada, M., Kuwahara, K., Izumi, T., et al. 2002. Guanylyl cyclase-A inhibits angiotensin II type 1A receptor-mediated cardiac remodeling, an endogenous protective mechanism in the heart. Circulation, 106(13): 1722-1728. doi:10. 1161/01.CIR.0000029923.57048.61. PMID:12270869.
10. Li, Y., Kishimoto, I., Saito, Y., Harada, M., Kuwahara, K., Izumi, T., et al. 2004. Androgen contributes to gender-related cardiac hypertrophy and fibrosis in mice lacking the gene encoding guanylyl cyclase-A. Endocrinology, 145(2): 951-958. doi:10. 1210/en.2003-0816. PMID:14592959.
11. Li, Y., Saito, Y., Kuwahara, K., Rong, X., Kishimoto, I., Harada, M., et al. 2010. Vasodilator therapy with hydralazine induces angiotensin AT receptor-mediated cardiomyocyte growth in mice lacking guanylyl cyclase-A. Br. J. Pharmacol. 159(5): 1133-1142. doi:10.1111/j.1476-5381.2009.00619.x. PMID:20136844.
12. Lopez, M.J., Wong, S.K., Kishimoto, I., Dubois, S., Mach, V., Friesen, J., et al. 1995. Salt-resistant hypertension in mice lacking the guanylyl cyclase-A receptor for atrial natriuretic peptide. Nature (Lond.), 378 (6552): 65-68. doi:10.1038/378065a0. PMID:7477288.
13. Mizuno, Y., Yasue, H., Oshima, S., Yoshimura, M., Ogawa, H., Morita, E., et al. 1997. Effects of angiotensin-converting enzyme inhibitor on plasma B-type natriuretic peptide levels in patients with acute myocardial infarction. J. Card. Fail. 3(4): 287-293. doi:10.1016/S1071-9164(97)90028-2. PMID:9547443.
14. Morita, E., Yasue, H., Yoshimura, M., Ogawa, H., Jougasaki, M., Matsumura, T., et al. 1993. Increased plasma levels of brain natriuretic peptide in patients with acute myocardial infarction. Circulation, 88(1): 82-91. PMID:8319360.
15. Nakanishi, M., Saito, Y., Kishimoto, I., Harada, M., Kuwahara, K., Takahashi, N., et al. 2005. Role of natriuretic peptide receptor guanylyl cyclase-A in myocardial infarction evaluated using genetically engineered mice. Hypertension, 46(2): 441-447. doi:10.1161/01.HYP.0000173420.31354.ef. PMID:15998711.
16. Nakao, K., Ogawa, Y., Suga, S., and Imura, H. 1992. Molecular biology and biochemistry of the natriureteic peptide system II: Natriureteic peptide receptors. J. Hypertens. 10(10): 1111-1114. doi:10.1097/00004872-199210000-00002. PMID:1334991.
17. Sabrane, K., Kruse, M.N., Fabritz, L., Zetsche, B., Mitko, D., Skryabin, B.V., et al. 2005. Vascular endothelium is critically involved in the hypotensive and hypovolemic actions of atrial natriuretic peptide. J. Clin. Invest. 115(6): 1666-1674. doi:10. 1172/JCI23360. PMID:15931395.
18. Sabrane, K., Kruse, M.N., Gazinski, A., and Kuhn, M. 2009. Chronic endothelium-dependent regulation of arterial blood pressure by atrial natriuretic peptide: role of nitric oxide and endothelin-1. Endocrinology, 150(5): 2382-2387. doi:10.1210/en.2008-1360. PMID:19179430.
19. Tamura, N., Ogawa, Y., Chusho, H., Nakamura, K., Nakao, K., Suda, M., et al. 2000. Cardiac fibrosis in mice lacking brain natriuretic peptide. Proc. Natl. Acad. Sci. U.S.A. 97(8): 4239-4244. doi:10. 1073/pnas.070371497. PMID:10737768.
20. Tang, K.M., Wang, G.R., Lu, P., Karas, R.H., Aronovitz, M., Heximer, S.P., et al. 2003. Regulator of G-protein signaling-2 mediates vascular smooth muscle relaxation and blood pressure. Nat. Med. 9(12): 1506-1512. doi:10.1038/nm958. PMID: 14608379.
21. Tokudome, T., Kishimoto, I., Horio, T., Arai, Y., Schwenke, D.O., Hino, J., et al. 2008. Regulator of G-protein signaling subtype 4 mediates antihypertrophic effect of locally secreted natriuretic peptides in the heart. Circulation, 117(18): 2329-2339. doi:10. 1161/CIRCULATIONAHA.107.732990. PMID:18443239.
22. Zhang, Q., Saito, Y., Naya, N., Imagawa, K., Somekawa, S., Kawata, H., et al. 2008. The specific mineralocorticoid receptor blocker eplerenone attenuates left ventricular remodeling in mice lacking the gene encoding guanylyl cyclase-A. Hypertens. Res. 31(6): 1251-1256. doi:10.1291/hypres.31.1251. PMID:18716375.